Hematology

Latest News

Modern Medical Technologies | Image credit: Prostock-studio - stock.adobe.com
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML

August 16th 2025

Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com
AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

August 14th 2025

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
QRISK3 Tool Predicts Thrombotic Events in ET, PV

August 8th 2025

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

August 7th 2025

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Modulating cholesterol metabolism in patients with CLL could improve T-cell function and possibly open up new therapeutic avenues to treat the disease. | Image credit: keetazalay - stock.adobe.com
March 11th 2025

Modulating Cholesterol Metabolism Could Open Therapeutic Pathways in CLL

Jared Kaltwasser
Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.
Fred Locke, MD, Moffitt Cancer Center and Research Institute
March 7th 2025

Overcoming Delays in CAR T for Large B-Cell Lymphoma

Maggie L. Shaw Frederick L. Locke, MD
Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen receptor (CAR) T-cell therapy, specifically allogeneic, which uses healthy donor cells.
Andrew Kuykendall, MD, Moffitt Cancer Center
March 5th 2025

Managing Polycythemia Vera to Reduce Risks and Improve Lives

Maggie L. Shaw Andrew Kuykendall, MD
Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells.
Ibrutinib tablets | Image credit: CLShebley – stock.adobe.com
March 5th 2025

Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better

Hayden E. Klein
Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.
BalanceIssues | Image Credit: © Bangkok Click Studio-stock.adobe.com
February 28th 2025

Falls, Balance Issues Signal Higher ICANS Risk in NHL

Tim Cortese
Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Sabarish Ayyappan, MD
February 27th 2025

Cost-Effectiveness Strategies Vital for Streamlining Care in Hematologic Malignancies

Kyle Munz Sabarish Ayyappan, MD
More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.
Sabarish Ayyappan, MD
February 24th 2025

Optimizing Approaches to CAR T, Bispecific Therapies in Myeloma and Lymphoma

Kyle Munz Sabarish Ayyappan, MD
Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.
Frederick L. Locke, MD
February 24th 2025

Allogeneic vs Autologous CAR T-Cell Therapy Explained

Maggie L. Shaw Frederick L. Locke, MD
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy produced durable responses in relapsed/refractory large B-cell lymphoma.
Sabarish Ayyappan, MD
February 20th 2025

Geographic Barriers Impede Access to Novel Cancer Treatments

Kyle Munz Sabarish Ayyappan, MD
In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.
A rituximab and lenalidomide combination (R-len) for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials | image credit: MQ-Illustrations - stock.adobe.com
February 18th 2025

Real-World Data Support Rituximab Plus Lenalidomide in NHL

Kyle Munz
A rituximab and lenalidomide combination for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials.
Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com
February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Kyle Munz
Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.
FDA approval | Image Credit: © wladimir1804 - stock.adobe.com
Published: February 12th 2025 | Updated: February 12th 2025

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL

Maggie L. Shaw
Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).
Patient talking to doctor in appointment. | Image credit: Chinnapong – stock.adobe.com
February 10th 2025

Academic Cancer Centers See Longer Survival in CLL, MCL Than Community Centers

Hayden E. Klein
Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.
Mikkael Sekeres, MD
February 7th 2025

Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS

Rose McNulty Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioning in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Non-Hodgkin Lymphoma wordcloud | Image Credit: © kalpis-stock.adobe.com.jpeg
February 7th 2025

Refining Remission Assessment in Aggressive B-Cell Lymphomas

Maggie L. Shaw
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.
cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com
February 7th 2025

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

Kyle Munz
The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.
Mikkael Sekeres, MD
February 6th 2025

Treosulfan Shown Effective, Safe as Conditioning for Allo-HSCT in AML/MDS

Mikkael A. Sekeres, MD Rose McNulty
Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, discussed data supporting the FDA approval of treosulfan as part of conditioning for allogeneic hematopoeitic stem cell transplantation (allo-HSCT).
Non-HodgkinLymphoma | Image Credit: © enterlinedesign-stock.adobe.com
January 30th 2025

SynKIR-310 Dosing for B-NHL Begins in CELESTIAL-301 Trial

Jordyn Sava
The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Extranodal NHL is not uncommon, comprising over 30% of NHL cases | image credit: Prostock Studio - stock.adobe.com
January 29th 2025

Study Expands Knowledge of Prognostic Markers in Extranodal NHL

Kyle Munz
Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.
There remains a need for more diagnostic accuracy in cases of soft tissue NHL | image credit: phonlamaiphoto - stock.adobe.com
January 27th 2025

MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL

Kyle Munz
Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.
Kirollos Hanna, PharmD
January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD
Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
FDA approved. | Image Credit: Pawel - stock.adobe.com
January 23rd 2025

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

Rose McNulty
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com
January 21st 2025

High Infection Risk in MM: Insights From the Preimmunotherapy Era

Kyle Munz
Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.
First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
January 18th 2025

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

Rose McNulty
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Man donating blood | Image Credit: © New Africa - stock.adobe.com
January 17th 2025

5 Medications That Defer Blood Donation

Maggie L. Shaw
Experts stress that persons wanting to donate blood should not stop any medications they are on, with some deferrals being permanent and others temporary.
MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com
January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

Kyle Munz
This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.
Donating blood can save more than 1 life | image credit: Creative Cat Studio - stock.adobe.com
January 10th 2025

5 Things to Know About Donating Blood

Kyle Munz
Here are 5 things individuals should know about the powerful impact of blood donation and the benefits becoming a donor can have for patients in need.
mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com
January 9th 2025

Study Advocates Immunological Value of COVID-19 Vaccination in MM

Kyle Munz
Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.
MRD ahead of allo-HSCT showed prognostic value in patients with AML and MDS. | Image credit: keetazalay - stock.adobe.com
January 6th 2025

MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

Kimberly Rath, PharmD
A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Among 55 evaluable samples analyzed, QPOP achieved an 87.3% success rate in generating individualized drug sensitivity reports. | Image credit: Eleni - stock.adobe.com
January 6th 2025

Functional Precision Medicine Tool Predicts Treatment Response in AML

Kimberly Rath, PharmD
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug combination sensitivities, paving the way for improved treatment strategies and outcomes in acute myeloid leukemia (AML).
<12345678
...
28>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo